Oppenheimer Lifts Pharvaris Target to $75 After Oral HAE Pill Cuts Attacks by 83% Oral deucrictibant XR met all endpoints; FDA filing eyed for H1 2027. Credit: Pharvaris Subscribe now Already have an account? Sign in.
